Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CCXINASDAQ:INCYNASDAQ:NBIXNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCXIChemoCentryx$51.99$51.95$14.95▼$52.00$3.71B1.221.68 million shs113 shsINCYIncyte$67.11+2.8%$60.88$53.56▼$83.95$12.99B0.682.30 million shs5.23 million shsNBIXNeurocrine Biosciences$125.00+0.4%$109.30$84.23▼$157.98$12.37B0.261.14 million shs1.26 million shsUTHRUnited Therapeutics$324.20-0.4%$299.78$266.98▼$417.82$14.62B0.58441,157 shs441,656 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCXIChemoCentryx0.00%0.00%0.00%0.00%0.00%INCYIncyte+0.09%+1.65%+4.45%-6.27%+13.01%NBIXNeurocrine Biosciences+1.51%+3.64%+13.57%+10.12%-8.01%UTHRUnited Therapeutics+2.89%+5.80%+10.48%+5.47%+18.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCXIChemoCentryxN/AN/AN/AN/AN/AN/AN/AN/AINCYIncyte4.2481 of 5 stars2.12.00.03.12.93.33.1NBIXNeurocrine Biosciences4.9764 of 5 stars4.45.00.02.93.42.53.1UTHRUnited Therapeutics4.8288 of 5 stars3.32.00.04.62.93.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCXIChemoCentryx 0.00N/AN/AN/AINCYIncyte 2.17Hold$72.538.08% UpsideNBIXNeurocrine Biosciences 2.86Moderate Buy$162.0029.60% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$393.0021.22% UpsideCurrent Analyst Ratings BreakdownLatest CCXI, UTHR, INCY, and NBIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2025INCYIncyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$61.006/2/2025NBIXNeurocrine BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$145.006/2/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$405.005/27/2025INCYIncyteTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$72.00 ➝ $73.005/6/2025NBIXNeurocrine BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/6/2025NBIXNeurocrine BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$137.00 ➝ $145.005/6/2025NBIXNeurocrine BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$160.00 ➝ $154.005/6/2025NBIXNeurocrine BiosciencesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$137.00 ➝ $152.005/6/2025NBIXNeurocrine BiosciencesBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Perform ➝ Market Perform$96.00 ➝ $115.005/6/2025NBIXNeurocrine BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$155.00 ➝ $165.005/6/2025NBIXNeurocrine BiosciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$138.00 ➝ $139.00(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCXIChemoCentryx$32.22M115.14N/AN/A$4.09 per share12.71INCYIncyte$4.41B2.94$0.52 per share128.94$17.82 per share3.77NBIXNeurocrine Biosciences$2.41B5.13$3.64 per share34.35$25.97 per share4.81UTHRUnited Therapeutics$2.99B4.88$19.49 per share16.63$127.35 per share2.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCXIChemoCentryx-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/AINCYIncyte$32.62M$0.32248.5610.260.410.77%0.05%0.04%7/29/2025 (Estimated)NBIXNeurocrine Biosciences$341.30M$2.9537.9919.320.7714.49%13.38%9.73%8/7/2025 (Estimated)UTHRUnited Therapeutics$984.80M$25.0614.2411.790.9740.31%19.22%16.15%7/30/2025 (Estimated)Latest CCXI, UTHR, INCY, and NBIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/5/2025Q1 2025NBIXNeurocrine Biosciences$0.70$0.08-$0.62$0.08$587.06 million$572.60 million4/30/2025Q1 2025UTHRUnited Therapeutics$6.29$6.63+$0.34$6.63$726.82 million$794.40 million4/29/2025Q1 2025INCYIncyte$1.01$1.16+$0.15$0.80$996.17 million$1.05 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCXIChemoCentryxN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/ANBIXNeurocrine BiosciencesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCXIChemoCentryx0.024.544.47INCYIncyte0.011.971.94NBIXNeurocrine BiosciencesN/A3.403.28UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCXIChemoCentryx81.09%INCYIncyte96.97%NBIXNeurocrine Biosciences92.59%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipCCXIChemoCentryx8.30%INCYIncyte17.80%NBIXNeurocrine Biosciences4.80%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCXIChemoCentryx17871.36 million65.43 millionOptionableINCYIncyte2,320193.57 million159.46 millionOptionableNBIXNeurocrine Biosciences1,20098.97 million95.42 millionOptionableUTHRUnited Therapeutics98045.11 million39.33 millionOptionableCCXI, UTHR, INCY, and NBIX HeadlinesRecent News About These CompaniesUnigestion Holding SA Makes New $2.67 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)June 3 at 6:53 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Milestone Asset Management LLCJune 3 at 5:21 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by GAMMA Investing LLCJune 3 at 4:40 AM | marketbeat.comCantor Fitzgerald Initiates Coverage of United Therapeutics (UTHR) with Overweight RecommendationJune 2 at 10:17 PM | msn.comUnited Therapeutics (NASDAQ:UTHR) Coverage Initiated at Cantor FitzgeraldJune 2 at 9:18 AM | marketbeat.comUnited Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock NewsJune 2 at 6:57 AM | gurufocus.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $3,476,770.00 in StockJune 2 at 4:29 AM | americanbankingnews.comAnalysts Set United Therapeutics Co. (NASDAQ:UTHR) PT at $392.00June 1 at 2:23 AM | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 SharesMay 31 at 5:28 PM | marketbeat.comSummit Global Investments Has $4.33 Million Position in United Therapeutics Co. (NASDAQ:UTHR)May 31 at 6:55 AM | marketbeat.comCalifornia State Teachers Retirement System Sells 6,861 Shares of United Therapeutics Co. (NASDAQ:UTHR)May 31 at 5:08 AM | marketbeat.comUniversal Beteiligungs und Servicegesellschaft mbH Takes $16.51 Million Position in United Therapeutics Co. (NASDAQ:UTHR)May 31 at 4:43 AM | marketbeat.comWhy Is United Therapeutics (UTHR) Up 9% Since Last Earnings Report?May 30, 2025 | zacks.com13,541 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by Lansforsakringar Fondforvaltning AB publMay 30, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 1,090 Shares of United Therapeutics Co. (NASDAQ:UTHR)May 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 30, 2025 | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comPolar Asset Management Partners Inc. Takes $7.80 Million Position in United Therapeutics Co. (NASDAQ:UTHR)May 28, 2025 | marketbeat.comLiquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal ChallengeMay 27, 2025 | benzinga.comGF Fund Management CO. LTD. Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)May 27, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in United Therapeutics Co. (NASDAQ:UTHR)May 27, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCCXI, UTHR, INCY, and NBIX Company DescriptionsChemoCentryx NASDAQ:CCXIChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.Incyte NASDAQ:INCY$67.11 +1.80 (+2.76%) Closing price 04:00 PM EasternExtended Trading$67.27 +0.16 (+0.24%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Neurocrine Biosciences NASDAQ:NBIX$125.00 +0.44 (+0.35%) Closing price 04:00 PM EasternExtended Trading$124.91 -0.09 (-0.08%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.United Therapeutics NASDAQ:UTHR$324.20 -1.28 (-0.39%) Closing price 04:00 PM EasternExtended Trading$321.75 -2.45 (-0.76%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
